Fuyuan Pharmaceutical: Subsidiary tablet production line passes GMP compliance inspection.

Fuyuan Pharmaceutical announced that its wholly-owned subsidiary Zhejiang Aisheng Pharmaceutical recently received a Drug GMP Compliance Inspection Notice. The inspection scope covers the tablet formulation I workshop and production line, with inspections taking place from October 15th to 17th, 2025, and the results meeting the relevant specifications. Among them, levothyroxine sodium tablets are one of the main products, with sales of approximately 1.035 billion yuan in the first three quarters of 2025 in China's three major and six major markets. Passing this inspection is beneficial for the company to maintain stable production capacity, but drug sales are subject to uncertainties due to factors such as national policies and market environment.